0SZI Stock Overview
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Corbus Pharmaceuticals Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$37.48 |
| 52 Week High | US$49.65 |
| 52 Week Low | US$3.12 |
| Beta | 2.47 |
| 1 Month Change | 7.30% |
| 3 Month Change | 371.89% |
| 1 Year Change | 268.85% |
| 3 Year Change | -31.36% |
| 5 Year Change | -82.93% |
| Change since IPO | -80.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0SZI | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -11.5% | -1.9% | -0.9% |
| 1Y | 268.8% | -30.5% | -1.8% |
Return vs Industry: 0SZI exceeded the UK Biotechs industry which returned -30.5% over the past year.
Return vs Market: 0SZI exceeded the UK Market which returned -1.8% over the past year.
Price Volatility
| 0SZI volatility | |
|---|---|
| 0SZI Average Weekly Movement | 92.8% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0SZI's share price has been volatile over the past 3 months.
Volatility Over Time: 0SZI's weekly volatility has increased from 53% to 93% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 19 | Yuval Cohen | www.corbuspharma.com |
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings.
Corbus Pharmaceuticals Holdings, Inc. Fundamentals Summary
| 0SZI fundamental statistics | |
|---|---|
| Market cap | US$396.12m |
| Earnings (TTM) | -US$44.60m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.9x
P/E RatioIs 0SZI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0SZI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$31.17m |
| Gross Profit | -US$31.17m |
| Other Expenses | US$13.44m |
| Earnings | -US$44.60m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.25 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -234.8% |
How did 0SZI perform over the long term?
See historical performance and comparison